Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$32 Mln
Revenue (TTM)
$16 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
24.51
EV/EBITDA
-2.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
26,198,400
CFO
$-92.54 Mln
EBITDA
$-114.75 Mln
Net Profit
$-169.49 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ocuphire Pharma (OCUP)
| -67.3 | -25.4 | -25.4 | -66.1 | -35.3 | -34.0 | -44.3 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Ocuphire Pharma (OCUP)
| -14.7 | -5.4 | -42.5 | -15.1 | -82.9 | -53.8 | 42.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ocuphire Pharma (OCUP)
|
1.0 | 31.7 | 16.5 | -14.1 | -87.8 | -31.2 | -- | 0.9 |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine... Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan. Read more
Interim President & Director
Mr. Richard J. Rodgers M.B.A.
CEO & Director
Mr. George Magrath M.B.A., M.D., M.S.
Headquarters
Farmington Hills, MI
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ocuphire Pharma Inc (OCUP) is $1.01 (NASDAQ) as of 21-Nov-2024 09:30 EDT. Ocuphire Pharma Inc (OCUP) has given a return of -35.34% in the last 3 years.
Since, TTM earnings of Ocuphire Pharma Inc (OCUP) is negative, P/E ratio is not available.
The P/B ratio of Ocuphire Pharma Inc (OCUP) is 0.93 times as on 22-Nov-2024, a 84 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Ocuphire Pharma Inc (OCUP) are Rs -- and Rs -- as of 04-Apr-2026.
Ocuphire Pharma Inc (OCUP) has a market capitalisation of $ 32 Mln as on 22-Nov-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Ocuphire Pharma Inc (OCUP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.12
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.